Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.54 |
| ▸ | MC3R | P41968 | 8/20 | 0.50 |
| ▸ | MC1R | Q01726 | 8/20 | 0.50 |
| ▸ | MC5R | P33032 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477067 | 0.88 | MC4R (0.51) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL6215075 | 0.88 | MC4R (0.51) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL6200844 | 0.87 | MC4R (0.58) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL6200842 | 0.84 | MC4R (0.55) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL6199053 | 0.83 | MC4R (0.48) | MC4RMC3RMC1RMC5R | |
| SCHEMBL6199056 | 0.83 | MC4R (0.48) | MC4RMC3RMC1RMC5R | |
| SCHEMBL6181458 | 0.83 | MC4R (0.51) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL6476762 | 0.82 | MC4R (0.63) | MC4RMC3RMC1RMC5R | |
| SCHEMBL7658037 | 0.81 | MC4R (0.53) | MC4RMC3RMC1RMC5RCYP3A4 | |
| SCHEMBL7658043 | 0.81 | MC4R (0.53) | MC4RMC3RMC1RMC5RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239835-A1 | Melanocortin receptor ligands | EBETINO FRANK H | 2005-10-27 | — | — | US | disclosed |
| US-20040010010-A1 | Melanocortin receptor ligands | PROCTER & GAMBLE COMPANY, THE | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239835-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC3R | MC4R 2/4885MC3R 3/4885MC1R 1/4885 |
| US-20040010010-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | MC4R 2/4885MC3R 4/4885MC1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.